Ionis Pharmaceuticals, Inc.
(NASDAQ : ISIS)

( )
ISIS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.29%73.880.9%$406.87m
AMGNAmgen Inc.
0.43%203.201.2%$406.65m
CELGCelgene Corporation
-0.26%87.381.2%$336.02m
BIIBBiogen Inc.
0.60%338.911.2%$283.91m
ILMNIllumina, Inc.
-0.15%350.373.5%$250.99m
REGNRegeneron Pharmaceuticals, Inc.
-1.19%383.702.6%$210.51m
EXASExact Sciences Corporation
1.90%74.1425.3%$195.91m
VRTXVertex Pharmaceuticals Incorporated
-0.29%176.601.9%$160.16m
SRPTSarepta Therapeutics, Inc.
-1.06%151.9516.4%$125.05m
AAgilent Technologies, Inc.
0.93%69.571.5%$122.17m
ALXNAlexion Pharmaceuticals, Inc.
0.95%121.972.0%$111.91m
ALNYAlnylam Pharmaceuticals, Inc
1.14%94.829.7%$95.17m
BMRNBioMarin Pharmaceutical Inc.
0.21%99.774.4%$93.85m
NKTRNektar Therapeutics
-2.81%56.695.6%$93.02m
VKTXViking Therapeutics, Inc.
0.98%19.650.9%$89.56m

Company Profile

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.